RayBiotech offers monoclonal and polyclonal antibodies against SARS-CoV-2 (COVID-19) proteins, including the Nucleocapsid protein (N-protein) and multiple domains and variants of the Spike protein (S-protein). The polyclonal antibodies for COVID-19 are produced from antiserum of rabbits immunized with a recombinant SARS-CoV-2 protein derived from E.coli or transfected human HEK293 cells. The monoclonal antibodies are produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with the immunogen. Antibody pairs, neutralizing antibodies, and antibodies to the human Angiotensin-Converting Enzyme 2 (ACE2) receptor are all also available.

Antibodies bind to specific sequences of amino acids, which are typically 5 - 8 residues in length. These sequences are known as "epitopes." Monoclonal antibodies bind to one epitope whereas polyclonal antibodies bind to multiple epitopes. This major difference is because each monoclonal antibody is derived from one hybridoma cell line whereas each polyclonal antibody is actually a pool of antibodies that are produced in response to an immunogen.

Typical Data

Western blot image of an antibody (cat# 130-10849) binding to recombinant wild-type and variant SARS-CoV-2 Spike proteins (0.25 µg/lane). 1) Wild-type, 2) N501Y; 3) E484K; 4) D614G; 5) HV69-70 deletion, N501Y, D614G; 6) K417N, E484K, N501Y (B.1.351 variant); and 7) K417T, E484K, N501Y (P.1 variant). L = standard ladder.